(Q38164873)

30 August 2017

title

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease (English)

1 reference

30 August 2017

4

Orly Weinreb

1 reference

30 August 2017

1

Moussa B H Youdim

1 reference

30 August 2017

2

Lana Kupershmidt

1 reference

30 August 2017

Tamar Amit

3

1 reference

30 August 2017

publication date

1 January 2014

1 reference

Parkinsonism and Related Disorders

30 August 2017

published in

1 reference

30 August 2017

volume

20 Suppl 1

1 reference

30 August 2017

page(s)

S132-6

1 reference

Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Psychosis, apathy, depression and anxiety in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

The therapeutic potential of monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Pharmacology of selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970032-4

7 January 2021

10.1016/S1353-8020(13)70032-4

Identifiers

DOI

1 reference

30 August 2017

1 reference